Genfit S.A. (0QT6.L)

4,0040 +0,0535 (+1,35%) Alla chiusura: 05:53PM BST

Genfit S.A.

Parc EurasantE
885, avenue EugEne AvinEe
Loos 59120
France
33 3 20 16 40 00
https://www.genfit.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 159

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Jean-Francois Mouney	Co-Founder & Chairman of the Board	359,01k	N/D	1955
Mr. M. Pascal Prigent	Chief Executive Officer	557,66k	N/D	1969
Prof. Bart Staels	Co-Founder & Chairman of the Scientific Advisory Board	N/D	N/D	1963
Mr. Thomas Baetz	Chief Financial Officer	N/D	N/D	1975
Mr. Pascal Caisey	Chief Operating Officer	N/D	N/D	1969
Dr. Meriam Kabbaj Ph.D.	Chief Technology Officer	N/D	N/D	1974
Dr. Dean W. Hum Ph.D.	Chief Scientific Officer	710,72k	N/D	1962
Mr. Jean-Christophe Marcoux	Chief Corporate Affairs Officer, Head of Investor Relations & Head of ESG	N/D	N/D	1978
Mr. Laurent Lannoo	Corporate Secretary & Director of Legal Affairs	N/D	N/D	1971
Ms. Stefanie Magner J.D.	Chief Compliance Officer & Executive VP of International Legal Affairs	N/D	N/D	1982

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

Governance aziendale

L'ISS Governance QualityScore di Genfit S.A. al 1 aprile 2024 è 5. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 7; diritti degli azionisti: 5; retribuzione: 3.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.